Posted by Michael Wonder on 07 Sep 2016
TGA publishes AusPAR for Opdivo (nivolumab)
7 September 2016 - The TGA has published an AusPAR for BMS' Opdivo.
The TGA approved nivolumab on 7 January 2016 for use:
- as monotherapy for the treatment of patients with unresectable (Stage III) or metastatic (Stage IV) melanoma
- in combination with Yervoy (ipilimumab) for the treatment of patients with metastatic (Stage IV) melanoma with M1c disease or elevated lactic dehydrogenase
- as monotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer
